Aktienanalyse zu Delcath Systems Inc (DCTH)DCTHDelcath Systems Inc

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA). It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Delcath Systems Inc is a good buy right now due to its strong revenue growth and positive analyst outlook. The current price is $14.08, and the company recently raised its 2026 revenue guidance to $104-$108 million, indicating strong confidence in future growth. Additionally, the gross margin has improved to 89.75% in Q2 2026, showcasing efficient operations. However, the main risk is the high forward P/E ratio of 232.56, which indicates that the stock is currently valued very high compared to its earnings potential.